Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

1) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition

Inclusion Criteria:

• The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy
• Aged over 20
• Consent form signed

Exclusion Criteria:

• pregnant or lactating women
• subjects with familial hypercholesterolemia
• uncontrolled hypertension or DM
• Thyroid dysfunction
• Active liver disease (transaminase or bilirubin > 1.5 x NL)
• Serum creatinine > 2 mg/dL
• Included in other clinical trials within 3 months
• using of other medication: fish oil, fibric acid derivatives, niacin, systemic corticosteroid, thiazolidinedione